Innovating Works

Exomnis Biotech

Desconocido
PREDICT: A new era in personalised medicine Radiomics as decision support tool for diagnostics and theragnos... EXOMNIS BIOTECH participó en un H2020: H2020-MSCA-ITN-2017 The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of per...
2017-08-29 - 2022-03-31 | Financiado
CMI2T IA: Harmless Clostridium bacteria as a highly targeted continuous delivery system for immunomodulatory... EXOMNIS BIOTECH tramitó un H2020: H2020-INNOSUP-2016-2017 DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treat...
2017-02-28 - 2018-08-31 | Financiado
IMMUNOSABR: Clinical proof of concept through a randomised phase II study a combination of immunotherapy and st... EXOMNIS BIOTECH participó en un H2020: H2020-SC1-2016-2017 IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-m...
2016-12-12 - 2024-12-31 | Financiado
RADIATE: Radiation Innovations for Therapy and Education EXOMNIS BIOTECH participó en un H2020: H2020-MSCA-ITN-2014 Approximately 45-60% of all cancer patients are treated with radiotherapy. Some of these patients have a good outcome, but in other cases th...
2014-12-05 - 2019-02-28 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.